Analyst Michael Matson of Needham reiterated a Buy rating on Establishment Labs Holdings, boosting the price target to $70.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Michael Matson has given his Buy rating due to a combination of factors including Establishment Labs Holdings’ strong financial performance in the third quarter of 2025. The company exceeded market expectations with its revenue and adjusted EBITDA, showing a significant improvement in revenue growth from the previous quarter. Additionally, the company’s gross margin and adjusted EBITDA margin have both increased substantially year-over-year, with the EBITDA margin turning positive for the first time.
Matson also highlights the company’s optimistic outlook, as management anticipates continued positive EBITDA margins and further growth in the upcoming quarter. The promising financial trajectory and the company’s unique position in the small-cap med tech sector contribute to the positive rating. Consequently, Matson has raised the price target for ESTA to $70, reflecting the company’s accelerating growth and favorable market conditions.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $77.00 price target.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ESTA in relation to earlier this year.